Your browser doesn't support javascript.
loading
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI.
Redondo, Sara; García-Cadenas, Irene; Vila, Antonio; Esquirol, Albert; Portos, J M; Novelli, Silvana; Saavedra, Silvana; Moreno, Carol; Garrido, Ana; Arguello-Tomas, Miguel; Oñate, Guadalupe; López-Pardo, Jordi; Caballero, Ana-Carolina; Miqueleiz, Sara; Briones, Javier; Sierra, Jorge; Sancho, Gemma; Martino, Rodrigo.
Afiliação
  • Redondo S; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • García-Cadenas I; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Vila A; Radiotherapy Oncology Department, Hospital de la Sant Creu i Sant Pau, Barcelona, Spain.
  • Esquirol A; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Portos JM; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Novelli S; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Saavedra S; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Moreno C; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Garrido A; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Arguello-Tomas M; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Oñate G; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • López-Pardo J; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Caballero AC; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Miqueleiz S; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Briones J; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Sierra J; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Sancho G; Radiotherapy Oncology Department, Hospital de la Sant Creu i Sant Pau, Barcelona, Spain.
  • Martino R; Hematology Department, Hospital de la Sant Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
Eur J Haematol ; 111(1): 146-153, 2023 Jul.
Article em En | MEDLINE | ID: mdl-37058419
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido